logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Summer 2017
Recro Pharma Inc.
File NDA for IV Meloxicam
Treatment of acute postoperative pain.
Jun 2017
Nektar Therapeutics
Topline data from Amikacin Inhale Phase 3 Program
gram-negative pneumonia
Jun 2017
Gemphire Therapeutics Inc.
Topline results from phase 2b trial of Gemcabene (COBALT -1)
homozygous familial hypercholesterolemia
Jun 2017
bluebird bio Inc.
Early data from phase 3 trial of LentiGlobin drug product (HGB-207)
Transfusion-Dependent Beta-Thalassemia
Mid 2017
AVEO Pharmaceuticals, Inc.
Pre-planned futility analysis of phase 3 trial of Tivozanib (TIVO-3)
Advanced renal cell carcinoma
Mid 2017
Rexahn Pharmaceuticals inc.
Data from stage 1 of Phase IIa Proof-of Concept trial of RX-3117
Muscle Invasive Bladder Cancer
Mid 2017
Rexahn Pharmaceuticals inc.
Phase IIa data read-out of Archexin
Metastatic Renal Cell Carcinoma
Mid 2017
Karyopharm Therapeutics Inc.
Topine data readout of phase 2 trial of Selinexor (SOPRA)
patients with relapsed/refractory AML
Mid 2017
Karyopharm Therapeutics Inc.
Topline data readout from phase 2 portion of Phase 2/3 trial of oral Selinexor (SEAL)
advanced unresectable dedifferentiated liposarcoma
Mid 2017
Karyopharm Therapeutics Inc.
Topline data from phase 1/2 trial of KPT-9274
solid malignancies
Mid 2017
Nektar Therapeutics
Data from pivotal human abuse liability trial of NKTR-181 (SUMMIT-HAL)
chronic low back pain
Mid 2017
AstraZeneca PLC
AZN.L, AZN
PFS data from phase 3 trial of Durvalumab (MYSTIC)
1st-line non-small cell lung cancer
Mid 2017
Pacira Pharmaceuticals, Inc.
Topl-line data from phase 3 study of EXPAREL
Brachial plexus nerve block for rotator cuff/shoulder arthroplasty
Mid 2017
Pacira Pharmaceuticals, Inc.
Top line data from phase 3 study of EXPAREL
Femoral nerve block for total knee arthroplasty
Mid 2017
Spark Therapeutics
initial Phase 1/2 data of SPK-8011
Hemophilia A
Mid 2017
Bellerophon Therapeutics LLC
Results from phase 2 trial for INOpulse
Pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis
Mid 2017
RXi Pharmaceuticals Corp.
Complete read-out from phase 2a study of RXI-109-1402
Hypertrophic Scarring
Mid 2017
Xenon Pharmaceuticals Inc.
Data from phase 2b trial of TV-45070
post-herpetic neuralgia
Mid 2017
Marinus Pharmaceuticals
Top-line data from phase 2 trial of Ganaxolone
children with CDKL5 genetic disorder
Mid 2017
Array BioPharma Inc.
Data from part 2 of phase 3 trial of Binimetinib and Encorafenib (COLUMBUS)
BRAF-mutant advanced melanoma.
Mid 2017
Prothena Corporation plc
Interim analysis of phase Ib study of PRX003
psoriatic arthritis
Mid 2017
Theravance Biopharma Inc.
Data from Phase 1b trial of TD-1473
moderate to severe ulcerative colitis.
Mid 2017
Ardelyx, Inc
Data read-out from phase 3 study of Tenapanor (T3MPO-1)
irritable bowel syndrome with constipation (IBS-C)
Mid 2017
MEI Pharma, Inc.
Interim data from Phase 1b clinical study of ME-401
lymphomas
Mid 2017
Alnylam Pharmaceuticals Inc.
Data from phase 3 trial with Patisiran (APOLLO)
Hereditary TTR-mediated amyloidosis with polyneuropathy